Hepatitis C and human immunodeficiency virus infection
Hepatitis C and human immunodeficiency virus infection
复制标题
DOI：
10.1053/jhep.2002.36380
复制
发表时间：
2002-11-01
期刊：
影响因子：
13.5
通讯作者：
Thomas, DL
中科院分区：
文献类型：
--
作者：
Thomas, DL
在美国，估计有20万人同时感染丙型肝炎病毒（HCV）和人类免疫缺陷病毒（HIV）。由于使用高效抗逆转录病毒疗法延长了艾滋病毒感染者的生命，肝病已成为发病和死亡的一个重要原因，在某些情况下是主要原因。人类免疫缺陷病毒感染似乎对丙型肝炎感染的各个阶段都有不利影响，导致病毒持续性增加和HCV相关肝病的加速进展。反过来，丙型肝炎可能会影响艾滋病毒感染的管理，增加抗逆转录病毒药物引起的肝毒性的发生率。HIV感染者中丙型肝炎的医学管理仍然存在争议，部分原因是感染和潜在药物相互作用的复杂性，但主要是因为发表的信息很少。尽管如此，肝病的负担太高，不能在等待更好的数据的同时推迟对HIV/HCV合并感染者的管理。相反，今天丙型肝炎的管理必须基于无艾滋病毒感染者的数据以及对这两种感染的理解。需要对HIV/HCV合并感染者的治疗进行适当设计的研究，以帮助指导未来对这些患者的管理。
In the United States, an estimated 200,000 persons are infected with both hepatitis C virus (HCV) and human immunodeficiency virus (HIV). As the lives of HIV-infected persons have been prolonged by use of highly active antiretroviral therapy, liver disease has emerged as an important, and in some settings, the leading cause of morbidity and mortality. Human immunodeficiency virus infection appears to adversely affect all stages of hepatitis C infection, leading to increased viral persistence and accelerated progression of HCV-related liver disease. In turn, hepatitis C may affect the management of HIV infection, increasing the incidence of liver toxicity caused by antiretroviral medications. The medical management of hepatitis C in HIV-infected persons remains controversial, in part because of the complexity of both infections and potential drug interactions, but chiefly because there is so little published information. Nonetheless, the burden of liver disease is too high to delay management of HIV/HCV-coinfected persons while awaiting better data. instead, the management of hepatitis C today must be based on data generated on persons without HIV and an understanding of both infections. Properly designed studies of therapy in HIV/HCV-coinfected persons are needed to help guide management of these patients in the future.